RecruitingNCT05046080

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix

Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor


Sponsor

M.D. Anderson Cancer Center

Enrollment

70 participants

Start Date

Aug 6, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.


Eligibility

Sex: FEMALE

Inclusion Criteria1

  • Patients diagnosed with clear cell carcinoma of the cervix at MDACC

Interventions

OTHERElectronic Health Record Review

Medical records reviewed

OTHERLaboratory Biomarker Analysis

Correlative studies


Locations(1)

M D Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05046080